MAPK8 and pancreatic neoplasm: Bentamapimod (AS602801), an ATP-competitive inhibitor pan-JNK inhibitor, is effective at reducing cell survival and tumorigenesis in pancreatic cancers, glioblastomas and ovarian cancers [61,62,63].